Bio­Mar­in's Roc­ta­vian strug­gles con­tin­ue. Is a di­vest­ment in the fu­ture?

Less than a year in­to a rocky roll­out for its gene ther­a­py Roc­ta­vian, Bio­Marin is now talk­ing about whether the prod­uct might be a bet­ter fit out­side the com­pa­ny, and cut­ting sev­er­al pipeline pro­grams.

On Wednes­day, CEO Alexan­der Hardy said that the biotech com­pa­ny is look­ing at plans for the he­mo­phil­ia A treat­ment, which brought in just $800,000 in the first quar­ter. If up­take doesn’t im­prove, Hardy said Bio­Marin may con­sid­er cut­ting the drug from its port­fo­lio al­to­geth­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER